Glycemic Control of Type 2 Diabetes Mellitus
|
|
|
- Grace Green
- 10 years ago
- Views:
Transcription
1 Bahrain Medical Bulletin, Vol. 28, No. 3, September 2006 Glycemic Control of Type 2 Diabetes Mellitus Majeda Fikree* Baderuldeen Hanafi** Zahra Ali Hussain** Emad M Masuadi*** Objective: To determine the frequency of use of HbA1c level as an indicator for type 2 diabetes control and to identify the Glycaemia control among type 2diabetic patients. Design: A retrospective study. Setting: Dair Health Center. Method: Medical records of all diabetic patients were reviewed for having a test result of HBA1c and for the average level of this test from first of January till the end of December The time of record review was from first of April 2005 till the end of May Result: Among 383 type 2 diabetic patients treated at Dair Health Center during 2004, only 178 cases (46.5%) had HBA1c test. Out of these, twenty cases (11.2%) had an HBA1c level of 7% and below. There was no statistically significant difference between the mean of HBA1c for males and females. There was no statistically significant difference between the mean of HBA1c and the type of treatment. Conclusion: HBA1c was underused as an indicator for diabetic control in Dair health center. Furthermore, more stress on strict Glycemic control needs to be emphasized. Bahrain Med Bull 2006: 28(3): Type 2 diabetes mellitus is a chronic disease which results from insulin resistance, mainly caused by obesity, with a defect in compensatory insulin secretion. Glycosylated hemoglobin is abnormally high in diabetics with chronic hyperglycemia and reflects their metabolic control. It is produced by nonenzymatic condensation of glucose molecules with free amino groups on the globin component of hemoglobin. The major form of glycohemoglobin is termed hemoglobin A1c, which normally comprises only 4-6% of the total hemoglobin 1. * Consultant Family Physician and Head, Dair Health Center ** Physicians, Dair Health Center. Ministry of Health, Kingdom of Bahrain. ***Lecturer Bio-statistics, Department of Community Medicine Arabian Gulf University, Kingdom of Bahrain. 1
2 Improving glycemic control in patients with type 2 diabetes may be as important as, treating hypertension and dyslipedemia for the prevention of both microvascular and macrovascular complications, particularly when aggressive treatment is initiated at an early stage of the disease 2. A review of various published reports was published by Del prato, it concluded that hemoglobin A1c is the standard for monitoring glycemic control. The results in the U K prospective diabetes study indicated that each 1% decrease in HBA1c reduces the risk of mortality associated with diabetes by 21% and the risk of myocardial infarction by 14% 3. The care provided in (NBB at Dair) health center for diabetic patients was provided in the daily general clinic by family physicians and general practitioners. There was no assigned diabetic nurse for the health center till March 2006 which is after the conduction of the study. The aim of the study is to determine the frequency of use of HbA1c level as an indicator for type 2 diabetes control and to identify the glycemic control among type 2 diabetic patients. METHOD A register including all type 2 diabetes mellitus patients, at Dair was developed using the information provided by physicians and prescriptions from the pharmacy. A list of 383 patients was identified. All diabetic patients medical records were reviewed by three physicians during April and May Data such as name, CPR, gender, type of treatment of diabetes mellitus, and the average level of HbA1c level during the year 2004 was gathered from the medical records. The average readings of HbA1c was calculated when it was done more than once. The data was entered in a statistical program Statistical Product and Service Solutions ( SPSS ) version 13 and analyzed accordingly. Frequency tables were done for age, gender, type of treatment and hemoglobin A1C level. Means and standard deviations were compared for HBA1c levels, Anova and Independent T- Test were used to compare between the levels of HBA1c and the type of treatment and gender. RESULT The total number of type 2 diabetics studied was 383. One hundred and sixty-two ( 42.3 % ) were males and two hundred twenty one (57.7 %) were females. Their age ranges between 30 and 88 years with mean and standard deviation of ± Only 8.6% of type 2 diabetic cases were between 30 and 39 years, 55.6 were between 40 and 49 years old, while 35.8% were 60 years and above. (Table 1) 2
3 Table 1: The distribution of age groups and percentage of each age group. % N Age Group in years and over Total Three hundred twenty-seven cases (85.4%) of type 2 diabetic cases were on oral treatment, 24 cases (6.3%) were on both oral and insulin treatment, 23 cases were on insulin therapy and 6 cases (2.3%) were on diet alone. (Figure 1) Percentage Oral Both Insulin Diet Type of Treatment Figure 1: The type of treatment received by patients (%). The level of HBA1c ranges between 5.1% and 17.1%, the mean HBA1c level was 9.68 ± One hundred seventy-eight cases (46.5%) of type 2 diabetic cases had HBA1c done for them. Among those who had HBA1c tested, Only twenty cases (11.2%) were controlled with an average HBA1c test result of 7% or less while the majority 158 cases, (88.8%) were uncontrolled. (Table 2) 3
4 Table 2: The distribution of hemoglobin A1c level among cases who had HBA1c tested. % N HBA1c level > Total There was no significant correlation between HBA1c and age of the patients. (r= , p = 0.87). There was no statistically significant difference between the mean of HBA1c for males (9.7±2.2) and females (9.6±2.3) (p=0.81). There was no statistically significant difference between the mean of HBA1c and the type of treatment: (9.6±2.2 for oral), (9.8±2.8for insulin) and (10.5±2.0for both) (p=0.37). (Table 3) Table 3: The distribution of HBA1c according to the type of treatment and gender. Male Female Total P value** Type of N Mean ± SD N Mean ±SD N Mean ± SD treatment Oral ± ± ± Insulin ± ± ± both ± ± ± Total ± ± ± P value* *P value calculated based on F Test (ANOVA). ** P value calculated based on Independent T Test Note: The total number here who had the test done was 176, after omitting diabetics on diet who had the test since their umber was small for ANOVA test. DISCUSSION The percentage of controlled HBA1c in this study was 11.2% compared to 44% found by Shorr RI et al among type 2 diabetic persons on oral hypoglycemic drugs 4. Other 4
5 studies showed a percentage of controlled diabetes mellitus among 40.5% and 53% of cases 5, 6. The mean level of HBA1c among diabetic patients who had the results available was 9.6% ± 2.2. A similar level of mean HBA1c (9.2 ± 1.33) was found among type 2 diabetic persons at the baseline of a comparative study conducted in USA 7. Lower levels of mean glycosylated hemoglobin was found among type 2 diabetic patients in a study in USA ; mean HBA1c was 7.7% for persons aged 20 to 54 years, 7.64% for persons aged 55 to 64 years old 4. A mean glycosylated hemoglobin level of 7.5±1.73 was found in a study conducted in USA at a primary care setting among type 2 diabetes mellitus persons 5. There was no statistically significant relation between the HBA1c level and neither gender nor the type of treatment. This finding over emphasizes that other factors should be studied and tackled accordingly. Only of type 2 diabetes mellites persons in this study had HBA1c level tested, 88.8% diabetic patients, who had HBA1c done were uncontrolled. It might be due to patient s and or physician s factors; Patient s factors include: Compliance to follow up. Compliance to treatment. Physician s factors include: Improper follow up by physicians. Dependence of physicians on fasting blood sugar only as an indicator of control. Insufficient time of consultation and counseling. Unavailability of diabetic clinic. Rapid physicians turnover. These factors need to be investigated in further studies in order to improve the quality of care of type 2 diabetes in the primary health care setting. CONCLUSION HBA1c was underused as an indicator for diabetic control in Dair health center. Furthermore, more stress on strict glycemic control needs to be emphasized. 5
6 REFERENCES 1. Lawrence M, Tierney Jr, Stephen J, et al. Current Medical Diagnosis and Treatment 2000,39 th edition.lang Medical Books,2000; Vaag AA. Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study. Endocr Pract.2006;12 Suppl 1; Del Prato S.Takling hyperglycemia; a more comrehensive approach. Endocr Pract.2006;12 Suppl 1; Shorr RI, Franse L V, Resinick H E, et al. Glycemic control of older adults with type 2 diabetes: findings from the Third National Health and Nutrition Examination Survey, J Am Geriatric Soc.2000;48(3): Spann SJ, Nutting P A, Galliher J M, et al. Management of type 2 diabetes in the primary care setting: a practice-based research network study. Ann Fam. Med. 2006; 4(1): Wan Q, Harris M F, Jayasinghe U W, et al. Quality of diabetes care and coronary heart disease absolute risk in patients with type 2 diabetes mellites in Australian general practice. Qual Saf Health care. 2006;15(2); Jacober S J, Scism-Bacon J L, Zagar A J, et al. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.diabetes, Obesity and Metabolism; 2006, Vol. 8 Issue 4,
Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
THE IMPACT OF USING BLOOD SUGAR HOME MONITORING DEVICE TO CONTROL BLOOD SUGAR LEVEL IN DIABETIC PATIENTS
THE IMPACT OF USING BLOOD SUGAR HOME MONITORING DEVICE TO CONTROL BLOOD SUGAR LEVEL IN DIABETIC PATIENTS Alshammari S., *Al-Jameel N., Al-Johani H, Al-Qahtani A., Al-Hakbani A., Khan A. and Alfaraj S.
COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL
Malaysian Journal of Pharmaceutical Sciences, Vol. 5, No. 1, 19 23 (2007) COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL TRI MURTI ANDAYANI* AND IKE IMANINGSIH
FORWARDHEALTH PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR HYPOGLYCEMICS, INSULIN LONG-ACTING
DEPARTMENT OF HEALTH SERVICES STATE OF WISCONSIN Division of Health Care Access and Accountability Wis. Admin. Code DHS 107.10(2) FORWARDHEALTH PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR HYPOGLYCEMICS,
Statistics of Type 2 Diabetes
Statistics of Type 2 Diabetes Of the 17 million Americans with diabetes, 90 percent to 95 percent have type 2 diabetes. Of these, half are unaware they have the disease. People with type 2 diabetes often
Department Of Biochemistry. Subject: Diabetes Mellitus. Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage.
Department Of Biochemistry Subject: Diabetes Mellitus Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage. Diabetes mellitus : Type 1 & Type 2 What is diabestes mellitus?
How To Determine The Prevalence Of Microalbuminuria
Research Journal of Pharmaceutical, Biological and Chemical Sciences Prevalence of Microalbuminuria in relation to HbA1c among known Type2 Diabetic Patients in Puducherry population Muraliswaran P 1 *,
Improving drug prescription in elderly diabetic patients. FRANCESC FORMIGA Hospital Universitari de Bellvitge
Improving drug prescription in elderly diabetic patients FRANCESC FORMIGA Hospital Universitari de Bellvitge High prevalence, but also increases the incidence. The older the patients, the higher the percentages
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
Diabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital
Research Article Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital *T. JANAGAN 1, R. KAVITHA 1, S. A. SRIDEVI
Diabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy
Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy Judith Long, MD,RWJCS Perelman School of Medicine Philadelphia Veteran Affairs Medical Center Background Objective Overview Methods
Using a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes
Special Series: AAFP Award-winning Research Papers Vol. 31, No. 5 331 Using a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes Gary Ruoff, MD; Lynn S. Gray, MD, MPH
GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*
71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the
Baskets of Care Diabetes Subcommittee
Baskets of Care Diabetes Subcommittee Disclaimer: This background information is not intended to be a comprehensive scientific discussion of the topic, but rather an attempt to provide a baseline level
A prospective study on drug utilization pattern of anti-diabetic drugs in rural areas of Islampur, India
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (5):33-37 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
Measure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care
Measure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
Practical Applications of Insulin Pump Therapy in Type 2 Diabetes
Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Wendy Lane, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title. Summary
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
Understanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
Diabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications
CHAPTER V DISCUSSION Background Diabetes mellitus is a chronic condition but people with diabetes can lead a normal life provided they keep their diabetes under control. Life style modifications (LSM)
Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University
Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die
MEDICAL POLICY POLICY TITLE DIABETIC SELF-MANAGEMENT TRAINING PROGRAM POLICY NUMBER MP- 2.076
Original Issue Date (Created): July 1, 2005 Most Recent Review Date (Revised): Effective Date: May 24, 2011 August 31, 2011- RETIRED I. POLICY Initial diabetic self-management training (DSMT) may be considered
PLAN OF RESEARCH. About. Degree of control Diabetics Mellitus in Ramadan months. Dr. Ali Mustafa Diploma F.M
PLAN OF RESEARCH About Degree of control Diabetics Mellitus in Ramadan months Dr. Somaya Algowder Consultant F.M Doctor In- charge Naim Health center By Dr. Amal Al Zawadi Specialist F.M 2005-2006 Dr.
CASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
Inpatient Treatment of Diabetes
Inpatient Treatment of Diabetes Alan J. Conrad, MD Medical Director Diabetes Services EVP, Physician Alignment Diabetes Symposium November 12, 2015 Objectives Explain Palomar Health goals for inpatient
Guidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
Criteria: CWQI HCS-123 (This criteria is consistent with CMS guidelines for External Infusion Insulin Pumps)
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Origination Date: 05/15 Revision Date(s): 05/2015 Developed By: Medical Criteria Committee 06/24/2015 External Infusion Insulin Pumps Page 1 of
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks
Background: Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 19, 2015 The Centers for Disease Control
BACKGROUND. ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes
BACKGROUND More than 25% of people with diabetes take insulin ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes Insulin identified as the most effective
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
CASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
Insulin Infusion Pumps
Medical Coverage Policy Insulin Infusion Pumps EFFECTIVE DATE: 09/01/2004 POLICY LAST UPDATED: 08/06/2013 OVERVIEW The policy addresses insulin infusion pumps that are worn externally and those that are
Updates for your practice March, 2013. Vol 2, Issue 14 TLALELETSO. Managing Complicated Diabetes
dates for your practice March, 2013. Vol 2, Issue 14 TLALELETSO Managing Complicated Diabetes Diabetes is increasingly common Managing diabetes and working as part of a multidisciplinary team is essential
Personalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach
Personalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach Riccardo Candido on behalf of the Personalized Therapy AMD Study Group Diabetes Canter A.S.S. 1 Triestina, Italy BACKGROUND
Investigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes.
PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title Investigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes.
Nutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT
1 Nutrition Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 2 Type 2 Diabetes: A Growing Challenge in the Healthcare Setting Introduction and background of type 2 diabetes:
Post-Transplant Diabetes: What Every Patient Needs to Know
Post-Transplant Diabetes: What Every Patient Needs to Know International Transplant Nurses Society What is Diabetes? Diabetes is an illness that effects how your body makes and uses a hormone called insulin.
The basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
Evaluating the Effectiveness of Physician and Clinical Pharmacist Patient Education and Disease Management in Diabetes Mellitus
Evaluating the Effectiveness of Physician and Clinical Pharmacist Patient Education and Disease Management in Diabetes Mellitus Sotheavy Vann Jackson-Hinds Comprehensive Health Center Jackson, MS Introduction
Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Support Supplement
CLINICALLY T E S T E D Natural Blood Sugar Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Metabolic Syndrome with Prediabetic
Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Authors: Dr. M. Love, Kathy Harrigan Reviewers:
Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
Diagnosis, classification and prevention of diabetes
Diagnosis, classification and prevention of diabetes Section 1 1 of 4 Curriculum Module II 1 Diagnosis, classification and presentation of diabetes Slide 2 of 48 Polyurea Definition of diabetes Slide 3
CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
An Introduction to Medication Adherence
An Introduction to Medication Adherence Medication Adherence Project (MAP) A project of the Cardiovascular Prevention & Control Program and the Fund for Public Health in New York Drugs don t work in patients
Overview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health
Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.
BARIATRIC SURGERY MAY CURE TYPE 2 DIABETES IN SOME PATIENTS
BARIATRIC SURGERY MAY CURE TYPE 2 DIABETES IN SOME PATIENTS Thomas Rogula MD, Stacy Brethauer MD, Bipand Chand MD, and Philip Schauer, MD. "Gastric bypass surgery has become a popular option for obese
Management of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)
Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the
Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.
Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused
Causes, incidence, and risk factors
Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,
Type 2 Diabetes. Tabinda Dugal GP Day 4/05/16
Type 2 Diabetes Tabinda Dugal GP Day 4/05/16 Diabetes Diabetes.a growing health crisis in Britain 869m per year 10% of NHS budget Projections.. 5 million by 2025 Youngest patient? T2DM Type 2 diabetes
Contractor Information. LCD Information. Local Coverage Determination (LCD): HbA1c (L32939) Contract Number 11202
Local Coverage Determination (LCD): HbA1c (L32939) Contractor Information Contractor Name Palmetto GBA opens in new window Contract Number 11202 Contract Type MAC - Part B LCD Information Document Information
Barriers for family doctors in Riyadh Military Hospital to initiate insulin therapy for patients with type 2 diabetes
Barriers for family doctors in Riyadh Military Hospital to initiate insulin therapy for patients with type 2 diabetes Mohammed S. Almesned, Mashhor N Alhantoushi Department of amily Medicine, king Saud
6.4 Diabetes. 6 Priority diseases and reasons for inclusion. Background. Developments since 2004. See Background Paper 6.4 (BP6_4DM.
6 Priority diseases and reasons for inclusion 6.4 Diabetes See Background Paper 6.4 (BP6_4DM.pdf) Background Diabetes and diabetes-related illnesses place an enormous burden on the health care systems
Intensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
There seem to be inconsistencies regarding diabetic management in
Society of Ambulatory Anesthesia (SAMBA) Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Review of the consensus statement and additional
EVALUATION OF A BASAL-BOLUS INSULIN PROTOCOL FROM CONTINUING DOSING EFFICACY AND SAFETY OPTIMIZATION IN NON-CRITICALLY ILL HOSPITALIZED PATIENTS
EVALUATION OF A BASAL-BOLUS INSULIN PROTOCOL FROM CONTINUING DOSING EFFICACY AND SAFETY OPTIMIZATION IN NON-CRITICALLY ILL HOSPITALIZED PATIENTS Joanne Archer, MSN, APRN, BC-ADM, Maureen T. Greene, PhD,
Challenges in Glycemic Control in Adult and Geriatric Patients. Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner
Challenges in Glycemic Control in Adult and Geriatric Patients Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner Provide an overview of diabetes prevalence; discuss challenges and barriers
REPORT ON DIABETES i
AFRICAN UNION UNION AFRICAINE UNIÃO AFRICANA AU CONFERENCE OF MINISTERS OF HEALTH (CAMH6) Sixth Ordinary Session, 22-26 April 2013, Addis Ababa, ETHIOPIA CAMH/Exp/6(VI) iv THEME: The Impact of Non-Communicable
The Joint Commission Advanced DSC Certification for Inpatient Diabetes Care
The Joint Commission Advanced DSC Certification for Inpatient Diabetes Care November 12, 2013 Caroline Isbey RN, MSN, CDE Associate Director Teresa Gomez Associate Project Director Specialist-SSM Carol
Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy. Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB
Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB Declarations I have received travel funding and speaker fees
Issued and entered this 20 th day of December 2010 by Ken Ross Commissioner ORDER I PROCEDURAL BACKGROUND
STATE OF MICHIGAN DEPARTMENT OF ENERGY, LABOR & ECONOMIC GROWTH OFFICE OF FINANCIAL AND INSURANCE REGULATION Before the Commissioner of Financial and Insurance Regulation In the matter of XXXXX Petitioner
Algorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
Diabetes Questionnaire
Diabetes Questionnaire UFS Duty of Disclosure (Insurance Contracts Act 1984) Your Duty of Disclosure Before you enter into a contract of life insurance with an insurer, you have a duty, under the Insurance
MEDICAL COVERAGE POLICY. SERVICE: Insulin Pump and Continuous Glucose Monitoring. PRIOR AUTHORIZATION: Required. POLICY:
Important note Even though this policy may indicate that a particular service or supply may be considered covered, this conclusion is not based upon the terms of your particular benefit plan. Each benefit
2012 Georgia Diabetes Burden Report: An Overview
r-,, 2012 Georgia Diabetes Burden Report: An Overview Background Diabetes and its complications are serious medical conditions disproportionately affecting vulnerable population groups including: aging
The first injection of insulin was given on
EFFECTIVE USE OF INSULIN THERAPY IN TYPE 2 DIABETES * Bernard Zinman, MDCM ABSTRACT Type 2 diabetes is a progressive disease; an individual s ability to secrete insulin in increasing amounts to overcome
Manitoba EMR Data Extract Specifications
MANITOBA HEALTH Manitoba Data Specifications Version 1 Updated: August 14, 2013 1 Introduction The purpose of this document 1 is to describe the data to be included in the Manitoba Data, including the
Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Number 84 Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus Summary Overview Clinical
British Columbia Pharmacy Association (BCPhA) Clinical Service Proposal Self-Monitoring of Blood Glucose in Type 2 Diabetes
British Columbia Pharmacy Association (BCPhA) Clinical Service Proposal Self-Monitoring of Blood Glucose in Type 2 Diabetes Introduction Self-monitoring of blood glucose (SMBG) is in widespread use among
Cardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
Diabetes Brief. Pre diabetes occurs when glucose levels are elevated in the blood, but are not as high as someone who has diabetes.
Diabetes Brief What is Diabetes? Diabetes mellitus is a disease of abnormal carbohydrate metabolism in which the level of blood glucose, or blood sugar, is above normal. The disease occurs when the body
Cochrane Quality and Productivity topics
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus NICE has developed the Cochrane Quality and Productivity (QP) topics to help the NHS identify practices
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized
Module I October 18-22, 2015 JW Marriott Marquis Hotel, Dubai, UAE
CME Accreditation is under process Module 1: Diabetes Facts and Diabetes in the Clinic Module 2: Nursing theory and educational (pedagogical) tools to advise and educate people with diabetes and their
Connecticut Diabetes Statistics
Connecticut Diabetes Statistics What is Diabetes? State Public Health Actions (1305, SHAPE) Grant March 2015 Page 1 of 16 Diabetes is a disease in which blood glucose levels are above normal. Blood glucose
1333 Plaza Blvd, Suite E, Central Point, OR 97502 * www.mountainviewvet.net
1333 Plaza Blvd, Suite E, Central Point, OR 97502 * www.mountainviewvet.net Diabetes Mellitus (in cats) Diabetes, sugar Affected Animals: Most diabetic cats are older than 10 years of age when they are
Cardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
Upstate New York adults with diagnosed type 1 and type 2 diabetes and estimated treatment costs
T H E F A C T S A B O U T Upstate New York adults with diagnosed type 1 and type 2 diabetes and estimated treatment costs Upstate New York Adults with diagnosed diabetes: 2003: 295,399 2008: 377,280 diagnosed
ETIOLOGIC CLASSIFICATION. Type I diabetes Type II diabetes
DIABETES MELLITUS DEFINITION It is a common, chronic, metabolic syndrome characterized by hyperglycemia as a cardinal biochemical feature. Resulting from absolute lack of insulin. Abnormal metabolism of
WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES. Living your life as normal as possible
WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES DEDBT01954 Lilly Deutschland GmbH Werner-Reimers-Straße 2-4 61352 Bad Homburg Living your life as normal as possible www.lilly-pharma.de www.lilly-diabetes.de
Statins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
Health Innovation Challenge - Chronic Disease Management. Haley Augustine & Rakesh Gupta Dalhousie University: Medical School
Haley Augustine & Rakesh Gupta 1 Health Innovation Challenge - Chronic Disease Management Haley Augustine & Rakesh Gupta Dalhousie University: Medical School Professor: Lynette Reid, [email protected]
Jill Malcolm, Karen Moir
Evaluation of Fife- DICE: Type 2 diabetes insulin conversion Article points 1. Fife-DICE is an insulin conversion group education programme. 2. People with greater than 7.5% on maximum oral therapy are
